4589 healthy nulliparous women who were 13 to 21 weeks pregnant were randomly assigned to receive daily treatment with either 2g of elemental calcium or placebo for the remainder of their pregnancies in1992-1995. Calcium supplementation did not significantly reduce the incidence or severity of preeclampsia or delay its onset. In subsequent analysis, the biological samples stored from the trial have been used to determine the associations between angiogenic factors, cell free DNA, thyroid hormone, and other biomarkers on the risk of developing preeclampsia. Other publications have also identified additional risk factors and consequences of preeclampsia with few investigations regarding gestational diabetes. Dr. Richard Levine is the original PI for the study and led numerous investigations using the biospecimens collected from CPEP to investigate the etiology of preeclampsia. After Dr. Levine's passing, Dr. Yeung has been continuing this work. Additional analyses utilizing the study database and specimen repository are being performed.
|Young, Brett; Levine, Richard J; Salahuddin, Saira et al. (2010) The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome. J Matern Fetal Neonatal Med 23:366-70|
|Levine, Richard J; Lindheimer, Marshall D (2009) First-trimester prediction of early preeclampsia: a possibility at last! Hypertension 53:747-8|
|Romero, Roberto; Nien, Jyh Kae; Espinoza, Jimmy et al. (2008) A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for J Matern Fetal Neonatal Med 21:9-23|